A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19

COVID-19 Clinical Trial

Official title:

A Phase II, Open Label, Single-Center, Clinical Trial to Assess Safety and Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04349631
• Other study ID #: HBCOVID01
• Status: Completed
• Phase: Phase 2
• Start date: April 20, 2020
• Est. completion date: November 25, 2020

Study information

• Verified date: September 2023
• Source: Hope Biosciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.

Description:

This is a Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease. 51 patients were enrolled. All patients have previously banked their own mesenchymal stem cells at Hope Biosciences. Eligible participants are either 65 years of age or older, have preexisting conditions, or are at high exposure risk of contracting COVID-19. The primary objective of this study is to provide immune support against COVID-19, measured by the presence or absence of adverse events and serious adverse events related to the study drug. In addition, participants will be monitored for overall clinical status by standard clinical laboratories and inflammatory markers. Participants will complete Short Form Health Survey (SF-36) and depression module (PHQ-9) questionnaires.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: November 25, 2020
• Est. primary completion date: November 25, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Subjects must meet the criteria for 1,2, OR 3, AND 4-7 to be eligible.

1. Men, and women 65 years of age or older (according to CDC provisions) OR

2. Participant works in healthcare facility or other well characterized high-risk environment OR

3. Has underlying conditions including but not limited to cardiopathies, diabetes mellitus, cancer, COPD, asthma or any other systemic autoimmune disease.

4. Subject must have previously banked their cells at Hope Biosciences

5. No signs or symptoms of infection, including but not limited to, body temperature >100 F and pulse rate > 100 BPM.

6. Subject provides written informed consent prior to initiation of any study procedures.

7. Agrees to the collection of venous blood per protocol.

8. Agrees to conformational testing for SARS-CoV-2 before end of study.

Exclusion Criteria:

Subjects must not have any of the following criteria to be eligible.

1. Women who are pregnant or lactating, or those who are not pregnant but do not take effective contraceptive measures

2. Patients who are participating in other clinical trials or have intake of investigational drug within the previous 30 days;

3. Inability to provide informed consent or to comply with test requirements;

4. Any medical disease or condition that, in the opinion of the site PI or sub-investigator, precludes study participation. Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial.

5. Patients who have received a stem cell treatment within one year.

6. Receipt of any other SARS-CoV-2 or other experimental coronavirus vaccine at any time prior to or during the study.

7. Patient currently or recently symptomatic for COVID-19 or anyone with COVID-19 associated symptoms within the past 30-days

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• HB-adMSCs
Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.

Locations

Country	Name	City	State
United States	Hope Biosciences Stem Cell Research Foundation	Sugar Land	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Hope Biosciences Stem Cell Research Foundation	Hope Biosciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Hospitalization for COVID-19	Number of subjects that require hospitalization for COVID-19	Week 0 through Week 26 (End of Study)
Primary	Incidence of Symptoms for COVID-19	Number of subjects that develop symptoms associated with COVID-19, such as fever, shortness of breath/difficulty breathing, cough	Week 0 through Week 26 (End of Study)
Secondary	Absence of Upper/Lower Respiratory Infection	Absence of upper/lower respiratory infection (with hospitalization criteria)	Week 0 through Week 26 (End of Study)
Secondary	Change From Baseline in Glucose	Change from baseline in level of glucose in the blood (mg/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Calcium	Change from baseline in level of calcium in the blood (mg/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Albumin	Change from baseline in level of albumin in the blood (g/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Total Protein	Change from baseline in level of total protein in the blood (g/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Sodium	Change from baseline in level of sodium in the blood (mmol/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Total Carbon Dioxide	Change from baseline in level of carbon dioxide in the blood (mmol/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Potassium	Change from baseline in level of potassium in the blood (mmol/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Chloride	Change from baseline in level of chloride in the blood (mmol/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Blood Urea Nitrogen (BUN)	Change from baseline in level of blood urea nitrogen (BUN) in the blood (mg/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Creatinine	Change from baseline in level of creatinine in the blood (mg/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Alkaline Phosphatase	Change from baseline in level of alkaline phosphatase in the blood (IU/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Alanine Aminotransferase	Change from baseline in level of alanine aminotransferase in the blood (IU/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Aspartate Aminotransferase	Change from baseline in level of aspartate aminotransferase in the blood (IU/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Total Bilirubin	Change from baseline in level of total bilirubin in the blood (mg/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Leukocytes	Change from baseline in level of leukocytes in the blood (x 10^9/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Erythrocytes	Change from baseline in erythrocytes in the blood (10^12/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Hemoglobin	Change from baseline in level of hemoglobin in the blood (g/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Hematocrit	Change from baseline in level of hematocrit in the blood (%)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Mean Corpuscular Volume	Change from baseline in mean corpuscular volume in the blood (fL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Mean Corpuscular Hemoglobin	Change from baseline in mean corpuscular hemoglobin in the blood (pg)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Mean Corpuscular Hemoglobin Concentration	Change from baseline in mean corpuscular hemoglobin in the blood (g/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Erythrocyte Distribution Width	Change from baseline in erythrocyte distribution width in the blood (%)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Neutrophils	Change from baseline in neutrophils in the blood (%) (leukocyte differential)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Lymphocytes	Change from baseline in lymphocytes in the blood (%) (leukocyte differential)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Monocytes	Change from baseline in monocytes in the blood (%) (leukocyte differential)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Eosinophils	Change from baseline in eosinophils in the blood (%) (leukocyte differential)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Basophils	Change from baseline in basophils in the blood (%) (leukocyte differential)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Platelets	Change from baseline in platelets in the blood (x 10^9/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Prothrombin Time	Change from baseline in prothrombin time in the blood (seconds)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in International Normalized Ratio (INR)	Change from baseline in international normalized ratio in the blood (INR) (ratio)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Tumor Necrosis Factor Alpha (TNF-alpha)	Change from baseline in tumor necrosis factor alpha (TNF-alpha) in the blood (ng/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Interleukin-6	Change from baseline in Interleukin-6 in the blood (ng/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Interleukin-10	Change from baseline in Interleukin-10 in the blood (ng/L)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in C-Reactive Protein	Change from baseline in C-Reactive Protein in the blood (mg/dL)	Weeks 0, 6, 14, 26
Secondary	Change From Baseline in Short Form (36) Health Survey (SF-36) Domain Average Physical Functioning	Short-form (36) Health Survey domain Average Physical Functioning; scored on a scale of 0-100; lower score equals more disability.	Weeks 0, 2, 6, 10, 14, 18, 22, 26
Secondary	Change From Baseline in Short Form (36) Health Survey (SF-36) Domain Average Role Limitations Due to Physical Health	Short-form (36) Health Survey domain Average Role Limitations due to Physical Health; scored on a scale of 0-100; lower score equals more disability.	Weeks 0, 2, 6, 10, 14, 18, 22, 26
Secondary	Change From Baseline in Short Form (36) Health Survey (SF-36) Domain Average Role Limitations Due to Emotional Problems	Short-form (36) Health Survey domain Average Role Limitations due to Emotional Problems; scored on a scale of 0-100; lower score equals more disability.	Weeks 0, 2, 6, 10, 14, 18, 22, 26
Secondary	Change From Baseline in Short Form (36) Health Survey (SF-36) Domain Average Energy/Fatigue	Short-form (36) Health Survey domain Average Energy/Fatigue; scored on a scale of 0-100; lower score equals more disability.	Weeks 0, 2, 6, 10, 14, 18, 22, 26
Secondary	Change From Baseline in Short Form (36) Health Survey (SF-36) Domain Average Emotional Well-being	Short-form (36) Health Survey domain Average Emotional Well-Being; scored on a scale of 0-100; lower score equals more disability.	Weeks 0, 2, 6, 10, 14, 18, 22, 26
Secondary	Change From Baseline in Short Form (36) Health Survey (SF-36) Domain Average Social Functioning	Short-form (36) Health Survey domain Average Social Functioning; scored on a scale of 0-100; lower score equals more disability.	Weeks 0, 2, 6, 10, 14, 18, 22, 26
Secondary	Change From Baseline in Short Form (36) Health Survey (SF-36) Domain Average Pain	Short-form (36) Health Survey domain Average Pain; scored on a scale of 0-100; lower score equals more disability.	Weeks 0, 2, 6, 10, 14, 18, 22, 26
Secondary	Change From Baseline in Short Form (36) Health Survey (SF-36) Domain Average General Health	Short-form (36) Health Survey domain Average General Health; scored on a scale of 0-100; lower score equals more disability.	Weeks 0, 2, 6, 10, 14, 18, 22, 26
Secondary	Change From Baseline in Patient Health Questionnaire 9 (PHQ-9) Total Score	Depression module; scores DSM-IV criteria to monitor severity of depression through 9 total questions; minimum score of 0, maximum score of 27, each question ranges from scores 0-3; higher scores mean worse outcome	Weeks 0, 2, 6, 10, 14, 18, 22, 26